Registry-listed formulations

etaracizumab · mesh:C112567

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    66.7%

    Based on 2 completed trials

    Completion Rate
    67%(2/3)
    Active Trials
    0(0%)
    Results Posted
    50%(1 trials)
    Terminated
    1(33%)

    Phase Distribution

    Phase 1/2
    2
    67%
    Phase 1
    1
    33%

    Phase Distribution

    1

    Early Stage

    2

    Mid Stage

    0

    Late Stage

    Phase Distribution3 total trials
    Phase 1Safety & dosage
    1(33.3%)
    Phase 1/2Combined phases
    2(66.7%)

    Highest Phase Reached

    Phase 1/2

    Trial Status & Enrollment

    Completion Rate

    66.7%

    2 of 3 finished

    Non-Completion Rate

    33.3%

    1 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    3

    all time

    Status Distribution
    Completed(2)
    Terminated(1)

    Detailed Status

    Completed2
    Terminated1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    3
    Active
    0
    Success Rate
    66.7%
    Most Advanced
    Phase 1/2

    Trials by Phase

    Phase 11 (33.3%)
    Phase 1/22 (66.7%)

    Trials by Status

    completed267%
    terminated133%

    Recent Activity

    0 active trials
    Showing 3 of 3
    completedphase_1

    Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma

    NCT00049712
    terminatedphase_1_2

    Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer

    NCT00684996
    completedphase_1_2

    Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer

    NCT00027729

    Clinical Trials (3)

    Showing 3 of 3 trials
    NCT00049712Phase 1

    Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma

    Completed
    NCT00684996Phase 1/2

    Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer

    Terminated
    NCT00027729Phase 1/2

    Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer

    Completed

    All 3 trials loaded

    Drug Details

    Intervention Type
    Varies by study
    Molecule Type
    Antibody
    Total Trials
    3

    External References

    ChEMBL
    CHEMBL5314357

    Names & Codes

    Trade Names

    Abegrinvitaxin

    Research Codes

    ETARATUZUMABHLM60MEDI-522